Haleon plc (LON:HLN - Get Free Report)'s stock price dropped 0.7% during mid-day trading on Monday . The company traded as low as GBX 359.95 ($4.88) and last traded at GBX 360.70 ($4.89). Approximately 10,357,583 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 24,445,391 shares. The stock had previously closed at GBX 363.17 ($4.92).
Wall Street Analysts Forecast Growth
HLN has been the subject of a number of research analyst reports. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a GBX 370 target price on shares of Haleon in a research report on Thursday, July 31st. Berenberg Bank decreased their price objective on Haleon from GBX 503 to GBX 500 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, JPMorgan Chase & Co. reissued an "underweight" rating on shares of Haleon in a report on Friday, August 1st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of GBX 435.
Read Our Latest Analysis on Haleon
Haleon Stock Performance
The company has a 50-day simple moving average of GBX 364.13 and a two-hundred day simple moving average of GBX 382.50. The company has a debt-to-equity ratio of 53.36, a quick ratio of 0.93 and a current ratio of 0.84. The firm has a market capitalization of £32.40 billion, a P/E ratio of 2,159.88, a PEG ratio of 1.49 and a beta of 0.19.
Haleon (LON:HLN - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported GBX 8.90 earnings per share (EPS) for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. As a group, equities analysts forecast that Haleon plc will post 19.5033282 EPS for the current year.
Insider Activity at Haleon
In other Haleon news, insider Dawn Allen sold 64,329 shares of the firm's stock in a transaction dated Monday, June 30th. The stock was sold at an average price of GBX 376, for a total transaction of £241,877.04. 0.01% of the stock is owned by company insiders.
About Haleon
(
Get Free Report)
Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.